Figure 2

The effect of adjuvant systemic therapy on prognostic impact of polymorphisms. (a) TP53 codon 72 and adjuvant chemotherapy alone (n = 137); (b) TP53 codon 72 and adjuvant chemotherapy with or without hormonal therapy (n = 281); (c) TP53 codon 72 and adjuvant hormonal therapy alone (n = 195); (d) TP53 codon 72 and no adjuvant systemic therapy (n = 77); (e) MDM2 SNP309 and adjuvant tamoxifen with or without luteinizing hormone-releasing hormone analog (n = 185). DFS, disease-free survival.